Right atrium thrombosis in patients on hemodialysis.

Vascular access has been the Achilles heel of hemodialysis for many years, and placement of temporary subclavian and internal jugular vein catheters has been a daily practice for the nephrologist. Now, concern about central vein stenosis, well described with the use of subclavian catheters in end-stage renal disease (ESRD), has prompted the use of internal jugular vein permanent catheters to avoid this complication, so as not to hinder future arteriovenous grafts. Permanent catheter access is not without its own special problems, and we describe here two patients that developed thrombosis of the right atrium while receiving hemodialysis through a permanent internal jugular catheter.

Quantitative ultrasonic detection of parenchymal structural change in diffuse renal disease.

OBJECTIVE: The authors determined whether quantitative ultrasound could be useful in the evaluation of diffuse renal disease. METHODS: Digitized radiofrequency ultrasound data were acquired from the kidneys of patients with biopsy-proven diffuse renal disease and transplant rejection (37 patients plus 18 normal volunteers). The results of the quantitative analysis were compared with histology results to determine if microscopic renal structure could be correlated with quantitative features such as scatterer size and scatterer spacing. The results also were analyzed using receiver operating characteristic analysis to determine if diffuse disease could be detected reliably using quantitative methods. RESULTS: The three most useful features in the native kidneys were mean scatterer spacing (MSS), sigma's, and average scatterer size (D). Using these features, it was possible to detect diffuse renal disease causing a decrease in renal function with an area under the ROC curve (Az) of 0.93. The feature D corresponded closely to histologically measured average glomerular diameters. For normals, D = 216 microns and glomerular diameter = 211 microns. No histologic correlate was found for scatterer spacing. In transplants, MSS and integrated backscatter were most useful for detecting rejection (Az = 0.87), and D in rejection was similar to the values for normal kidney and normally functioning transplants. CONCLUSIONS: The D value corresponds to glomerular diameter, and glomerular enlargement can be detected readily using quantitative ultrasound. Combinations of two to four quantitative features can detect diffuse renal disease and transplant rejection reliably.

Does low-calcium dialysate accelerate secondary hyperparathyroidism in continuous ambulatory peritoneal dialysis patients?

A lower-calcium dialysate has been advocated for continuous ambulatory peritoneal dialysis (CAPD) patients for the purpose of increasing oral calcium intake as a phosphate binder and decreasing the need for aluminum-containing phosphate binders and, hence, decreasing the risk of aluminum intoxication. Twelve CAPD patients were evaluated retrospectively after switching from a dialysate containing 3.5 mEq/L of calcium to a new dialysate containing 2.5 mEq/L of calcium. Patients were on the new dialysate for at least 1 year. Serum calcium, phosphate, alkaline phosphatase, aluminum, and intact or N-terminal parathyroid hormone (I-PTH, N-PTH) were measured. Calcium, phosphate, and aluminum did not change significantly. Alkaline phosphatase doubled, but was not statistically significant. I-PTH and N-PTH rose from 2.9 +/- 2.24 to 7.4 +/- 7.4 times normal (p < 0.012). Three of 7 patients who had x-ray evaluations before, during, and 1 year after change of dialysate had radiographic progression of bone disease. Three patients required a parathyroidectomy due to the development of severe secondary hyperparathyroidism. In conclusion, the indiscriminate use of dialysate containing 2.5 mEq/L of calcium, in CAPD patients, may place the patients at higher risk for progression of hyperparathyroidism.

Low-dose subcutaneous erythropoietin in continuous ambulatory peritoneal dialysis.

We evaluated changes in hematocrit in patients on continuous ambulatory peritoneal dialysis (CAPD) before and after the administration of erythropoietin (EPO). Thirty-five patients were evaluated at the beginning of treatment with CAPD and after an average of 3.5 years on CAPD; mean hematocrit (Hct) rose from 25.4 +/- 5.4% to 28.1 +/- 6.7% (P less than 0.001). In the period before EPO administration 11 patients required a total of 44 transfusions (one patient needed 23 transfusions). Fifteen patients were started on subcutaneous erythropoietin 3,000 units 3 times a week and were followed for a mean period of 6.3 months. Hct rose from 23.8 +/- 1.8% to 25.2 +/- 2.4% (P less than 0.01) within the first 2 weeks and up to 27.5 +/- 3.7% (P less than 0.01) in the fourth week. By the eighth week the target Hct (30 to 35%) was reached. During the next 5 months the EPO doses were adjusted to each patient's needs ranging between 2,000 U per week to 4,000 U 3 times per week. Mild hypertension was the only side effect seen in some of the patients. In conclusion low dose subcutaneous EPO is effective in managing the anemia of patients on CAPD with only minor side effects.

Ten years' experience with continuous ambulatory peritoneal dialysis.

Up to January 1989, 171 patients were trained at our center on continuous ambulatory peritoneal dialysis (CAPD), and 17 on continuous cyclic peritoneal dialysis (CCPD). Over 10 years, we have gained 5,068 patient-months experience. Patient survival was 60% and 31% at 5 and 10 years, respectively. In contrast, diabetics had a survival of 32% at 5 years. Major complications included 499 new episodes of peritonitis, 304 exit-site infections, 22 hernias, five bowel perforations, one hydrothorax, and three episodes of sclerosing encapsulating peritonitis. Our technique survival has been 62% and 40% at 5 and 10 years, respectively. We believe that CAPD is a viable dialysis technique for long-term treatment of chronic renal failure and it should be offered as an option to intermittent hemodialysis.

Polycystic kidneys do maintain good endocrine function.

We develop here the hypothesis that polycystic kidneys (PCK) may maintain, to a certain extent, the ability to perform endocrine functions. We know that patients with adult polycystic kidney disease (APCKD) produce more erythropoietin and maintain a higher hematocrit than patients with other primary diseases of the kidneys. It is possible that they synthesize more 1,25 and 24,25 Vit D3 and metabolize better the parathyroid hormone and other hormones. If it is correct, they may have fewer signs of secondary hyperparathyroidism and less bone marrow fibrosis which along with increased erythropoietin production would explain the higher hematocrit.

Chronic dialysis in a patient with cystic fibrosis.

To our knowledge this is the first case reported in the literature of a patient with cystic fibrosis and end-stage renal disease, who was on dialysis for 2 years. We discuss here the possible mechanisms responsible for what has been called 'the cystic fibrosis nephropathy' and its consequences.

Immune stimulation. A new approach in the treatment of glomerulonephritis.

We discuss here a new approach to the treatment of idiopathic membranous glomerulonephritis (IMGN). Steroids and cytotoxic drugs have been used during the last years for the treatment of this disease, but the results are controversial. We develop here the hypothesis that the pathogenesis of IMGN is a relative incompetence of the immune system in clearing foreign antigens. Therefore, most patients should benefit from immune stimulation in the direction of a greater and more avid immune response.

Pulmonary hemorrhage and glomerulonephritis in the absence of anti-glomerular basement membrane antibody.

We have described a case of pulmonary hemorrhage and idiopathic crescentic glomerulonephritis unrelated to anti-glomerular basement membrane antibodies and/or immune complexes. Although pulmonary hemorrhage was controlled dramatically with high doses of corticosteroids, renal function declined rapidly.

Sclerosing encapsulating peritonitis in rats induced by long-term intraperitoneal administration of antiseptics.

Continuous ambulatory peritoneal dialysis (CAPD) is an effective long-term treatment for renal failure. Sclerosing encapsulating peritonitis (SEP) is a rare but devastating complication of CAPD and may be caused by long-term peritoneal antiseptic exposure. We examined the peritoneal injury resulting from daily inoculations of moderately high concentrations of the following antiseptics: povidone-iodine, Dakin's solution, Amuchina, and Ampercide. After 4, 8, and 12 weeks of daily intraperitoneal injections in rats, a 10% solution of povidone-iodine in dialysis fluid caused a condition that mirrors human SEP. Animals had poor early weight gain, and gross necropsy examination revealed intestinal adhesions and a mesothelium that was sclerotically thickened. From 4 to 8 weeks the 10% povidone-iodine-injected animals showed progressive conditions and the prevalence of multiple encapsulating adhesions increased from 0/6 to 4/4, p = 0.005. Marked visceral mesothelial thickening in the 10% povidone-iodine-injected animals was quantitated after 4, 8, and 12 weeks at 92.0 +/- 11.6, 151.5 +/- 28.8, and 206.0 +/- 36.2 micron, respectively. Rats injected with dialysis fluid (controls) had normal-appearing mesothelial surfaces measured at 1.8 +/- 0.2, 2.4 +/- 0.2, and 2.2 +/- 0.2 micron after 4, 8, and 12 weeks, respectively. The marked thickening of the mesothelium in the 10% povidone-iodine group compared with the controls was highly significant, p less than 10(-8). We conclude that povidone-iodine, the most commonly used antiseptic in CAPD, caused severe tissue injury, whereas other antiseptic solutions, Dakin's, Amuchina, and Ampercide, at the similar dilution did not appear to cause mesothelial injury.(ABSTRACT TRUNCATED AT 250 WORDS)